Krystal Biotech, Inc. is a premium stock of StocksGuide. Please log in to activate an alert for Krystal Biotech, Inc..
Register for Free
Please register for free to add Krystal Biotech, Inc. to your portfolio.
Krystal Biotech, Inc. Stock News
$315.34
5.62%
Nasdaq, Nov 18, 04:00 pm EST.
Closed.
Why the stock moved
StocksGuide Unlimited β full access to AI analyses
With Unlimited you get the full AI functionality for Krystal Biotech, Inc.. π More detailed insights π Exclusive perspectives on opportunities & risks π Clear answers to your questions
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome Strong balance sheet, ending the quarter with $1.2 billion in cash and investments Board authorizes share repurchase program of u...
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be pr...
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the βCompanyβ or βKrystalβ) (NASDAQ: KRYS) today reported fin...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.